BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35055136)

  • 1. Cu(II) Binding Increases the Soluble Toxicity of Amyloidogenic Light Chains.
    Russo R; Romeo M; Schulte T; Maritan M; Oberti L; Barzago MM; Barbiroli A; Pappone C; Anastasia L; Palladini G; Diomede L; Ricagno S
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cu(II) binding to the λ6aJL2-R24G antibody light chain protein associated with light chain amyloidosis disease: The role of histidines.
    Pelaez-Aguilar AE; Mata-Salgado F; Morales-Ortiz A; Millán-Pacheco C; Olvera-Carranza C; Salgado-Delgado J; Pastor N; Rivillas-Acevedo L
    Int J Biol Macromol; 2024 Jun; 270(Pt 2):132393. PubMed ID: 38761898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation.
    Broggini L; Barzago MM; Speranzini V; Schulte T; Sonzini F; Giono M; Romeo M; Milani P; Caminito S; Mazzini G; Rognoni P; Merlini G; Pappone C; Anastasia L; Nuvolone M; Palladini G; Diomede L; Ricagno S
    J Mol Biol; 2023 Dec; 435(24):168320. PubMed ID: 37865287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
    Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
    J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
    Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
    J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
    Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
    Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
    Morgan GJ; Kelly JW
    J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.
    Peterle D; Klimtchuk ES; Wales TE; Georgescauld F; Connors LH; Engen JR; Gursky O
    J Mol Biol; 2021 Dec; 433(24):167310. PubMed ID: 34678302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
    Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
    Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
    Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
    J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.
    Diomede L; Romeo M; Rognoni P; Beeg M; Foray C; Ghibaudi E; Palladini G; Cherny RA; Verga L; Capello GL; Perfetti V; Fiordaliso F; Merlini G; Salmona M
    Antioxid Redox Signal; 2017 Sep; 27(9):567-582. PubMed ID: 28132512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity.
    Garofalo M; Piccoli L; Romeo M; Barzago MM; Ravasio S; Foglierini M; Matkovic M; Sgrignani J; De Gasparo R; Prunotto M; Varani L; Diomede L; Michielin O; Lanzavecchia A; Cavalli A
    Nat Commun; 2021 Jun; 12(1):3532. PubMed ID: 34112780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
    Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
    Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
    Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
    Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
    Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
    PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
    Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
    Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.
    Klimtchuk ES; Gursky O; Patel RS; Laporte KL; Connors LH; Skinner M; Seldin DC
    Biochemistry; 2010 Nov; 49(45):9848-57. PubMed ID: 20936823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.